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Background: The human polyomavirus BK expresses a 66 amino-acid peptide referred to as agnoprotein. Though
mutants lacking agnoprotein are severely reduced in producing infectious virions, the exact function of this peptide
remains incompletely understood. To elucidate the function of agnoprotein, we searched for novel cellular interaction
partners.
Methods: Yeast-two hybrid assay was performed with agnoprotein as bait against human kidney and thymus
libraries. The interaction between agnoprotein and putative partners was further examined by GST pull down,
co-immunoprecipitation, and fluorescence resonance energy transfer studies. Biochemical and biological studies
were performed to examine the functional implication of the interaction of agnoprotein with cellular target proteins.
Results: Proliferating cell nuclear antigen (PCNA), which acts as a processivity factor for DNA polymerase δ, was
identified as an interaction partner. The interaction between agnoprotein and PCNA is direct and occurs also in
human cells. Agnoprotein exerts an inhibitory effect on PCNA-dependent DNA synthesis in vitro and reduces cell
proliferation when ectopically expressed. Overexpression of PCNA restores agnoprotein-mediated inhibition of cell
proliferation.
Conclusion: Our data suggest that PCNA is a genuine interaction partner of agnoprotein and the inhibitory effect on
PCNA-dependent DNA synthesis by the agnoprotein may play a role in switching off (viral) DNA replication late in
the viral replication cycle when assembly of replicated genomes and synthesized viral capsid proteins occurs.
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Polyomaviruses are naked viruses with a circular double-
stranded DNA genome of approximately 5,000 base-pairs.
All polyomaviruses isolated so far seem to encode the
regulatory proteins large T-antigen and small t-antigen
and at least two capsid proteins VP1 and VP2 [1-3]. Some
PyVs encode a third capsid protein, VP3 [4]. The human
PyVs BK (BKPyV) and JC virus (JCPyV), and the monkey
PyV simian vacuolating virus 40 (SV40) encode an add-
itional regulatory protein referred to as agnoprotein [3,5].* Correspondence: ugo.moens@uit.no
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unless otherwise stated.Agnoprotein is highly conserved, especially the first 2/3
part of the peptide and is characterized by a hydrophobic
central region [6-10]. None of the recently characterized
human PyVs (KIPyV, WUPyV, Merkel cell PyV, HPyV 6,
HPyV7, trichodysplasia spinulosa-associated polyomavirus,
HPyV9, HPyV10, STLPyV and HPyV12) seem to express
agnoprotein [11-19]. An open reading frame encoding a
putative protein with sequence homology to agnoprotein
is also present in the genomes of simian virus 12 (Papio
ursinus), the white-fronted capuchin polyomavirus (Cebus
albifrons), yellow baboon polyomavirus 2 (Papio cynece-
phalus), and vervet monkey polyomavirus 2 (Chlorocebus
pygerythrus), [20-22]. However, the existence of agnopro-
tein encoded by these non-human primate PyVs remains
to be proven.his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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but studies with SV40 and JCPyV have demonstrated
that it is involved in viral DNA replication [23], nuclear
egress [24], transcriptional and post-transcriptional pro-
cesses [25,26], maturation [27,28], protein stability and
localization [29,30]. It can also act as a membrane-
inserting viral release promoting viroporin through inter-
action with adaptor protein complex 3 [31,32]. Moreover,
mutants deficient in agnoprotein are severely impaired in
viral DNA replication [28,33]. Less is known about BKPyV
agnoprotein, but because of its high similarity with JCPyV
(80% amino acid identity) and SV40 (63% amino acid
identity) it is likely that these proteins exert similar func-
tions. Indeed, cells transfected with BKPyV genomes defi-
cient in the agnogene produce none or significantly less
infectious particles compared to cells transfected with
wild-type genomes. Furthermore, BKPyV agnoprotein can
repress the activity of the late promoter [34,35]. Our group
also demonstrated that BKPyV agnoprotein may inter-
fere with secretion through its interaction with α-soluble
N-ethylmaleimide-sensitive fusion attachment protein, a
protein involved in disassembly of vesicles [36]. Interest-
ingly, conditioned medium obtained from rat CG4-OI
oligodendrocytes constitutively expressing JCPyV agno-
protein contain reduced amounts of several chemokines
[37]. It is however, not known whether JCPyV agnopro-
tein interferes with the expression or the secretion of
these chemokines.
Proliferating cell nuclear antigen (PCNA) is an essen-
tial component of the eukaryotic chromosomal DNA
replication machinery that together with DNA polymer-
ase (pol) δ ensure continuous DNA synthesis after DNA
polymerase α/primase synthesized the RNA/DNA pri-
mer [38-41]. Topologically, PCNA exists as a hollow
toroidal homotrimeric protein composed of individual
29 kDa subunits. One subunit consists of two lobes of β-
sheets and α-helices connected by the “interstrand con-
necting loops” [42,43]. The α-helices form a positively
charged inner ring that contacts the DNA, whereas the
β-sheets form an outer rim with an overall negative
charge distribution that provides an interaction platform
for other proteins. More than 100 different PCNA inter-
action partners have been described so far [38,44,45].
These interaction partners participate in a variety of cel-
lular processes such as DNA replication and repair,
DNA methylation, histone acetylation, sumoylation, cell
cycle control, and cell survival [38,46].
In the presented work we identified PCNA as a bona
fide BKPyV agnoprotein interaction partner and provide
evidence that agnoprotein inhibits PCNA-dependent
pols δ DNA synthesis in vitro. The activities of DNA re-
pair pols β and λ were unaffected by the presence of
agnoprotein. Moreover, overexpression of agnoprotein
reduced DNA synthesis in cell culture. Overexpressionof PCNA counteracted the inhibitory effect of agnopro-
tein on DNA synthesis. Although we did not investigate
the effect of agnoprotein on viral DNA replication, we
suggest a similar role since viral DNA synthesis depends
on PCNA and polδ. Turning off viral replication allows
viral genomes to be packed into infectious viral particles.
Results
BKV agnoprotein and PCNA interact in vitro and in vivo
To elaborate on the function of BKPyV agnoprotein, we
applied a yeast two hybrid screen using agnoprotein as
bait against human kidney and thymus libraries and
identified PCNA as a possible interacting partner (re-
sults not shown). To assure that this interaction takes
place in vitro and is direct, we first performed pull
down experiments with purified agnoprotein and PCNA
(Figure 1A). Purified PCNA was mixed with buffer (lanes
1 and 2), agnoprotein (lanes 3 and 4), lysate from non-
transfected HEK293 cells (lanes 7 and 8), or GST-agno
(lanes 11 and 12). GST-PCNA was also added to buffer
(lanes 9 and 10). Complexes were subsequently immuno-
precipitated (IP) with antibodies directed against PCNA.
The presence of proteins in the input (I) and the immuno-
precipitates (P) was monitored by using antibodies against
agnoprotein (WB: anti-agno; top panel left figure) and
PCNA (WB: anti-PCNA; bottom panel left figure). Simi-
larly, purified agnoprotein was incubated with buffer
(lanes 13 and 14), PCNA (lanes 15 and 16) and cell lysate
(lanes 19 and 20), or with GST-PCNA (lanes 23 and 24).
GST-agno with buffer and lysate of non-transfected
HEK293 cells alone were used as controls (lanes 17 and
18, and lanes 21 and 22). The reciprocal immunoprecipita-
tion with anti-agno antibodies was followed by western
blot with anti-PCNA antibodies (top panel, right figure)
and anti-agno antibodies (bottom panel, right figure). Our
results show a direct in vitro interaction between (GST)-
PCNA and (GST)-agnoprotein (lanes 4, 12, 16 and 24). A
band corresponding to ~18 kDa was detected with
anti-agno antibodies in samples containing purified agno-
protein (lanes 3, 4, 13–16, 19, 20, 23 and 24). This corre-
sponds probably to agnoprotein dimers (see further). It
should be noticed that purified PCNA has some additional
amino acids due to the cloning and this is reflected that
the protein migrates a bit slower than endogenous PCNA
(e.g. compare lanes 1–4 with 5 and 6, and lanes 15 and 16
with 17 and 19).
To access the existence of agnoprotein:PCNA in cells,
HEK293 cells were transfected with expression plasmids
for agnoprotein and either empty vector or a plasmid
encoding FLAG-tagged PCNA. Complexes were subse-
quently immunoprecipitated (IP) with antibodies directed
against PCNA. Agnoprotein could be detected in en-
dogenous PCNA/FLAG-PCNA and endogenous PCNA
































































































































































Figure 1 BKPyV agnoprotein and PCNA interact in vitro and in vivo. (A) In vitro pull down experiment shows direct interaction between
PCNA and agnoprotein. Purified agnoprotein, PCNA or GST-PCNA fusion protein were incubated alone or together in PBS (buffer) or with lysate
of HEK293 cells (cell lysate) at 4°C for 1 h. Complexes were immunoprecipitated with PCNA antibodies (IP:anti-PCNA; lanes 1–12) or with
antibodies against agnoprotein (IP:anti-agno; lanes 13–24). Samples were run on gel and western blot was performed with antibodies against
PCNA (WB:anti-PCNA) or against agnoprotein (WB: anti-agno) as indicated. I = input, P = precipitate. The position of GST-agno, agnoprotein,
GST-PCNA, purified PCNA and endogenous PCNA are indicated by arrows. The arrow with dashed line probably represents agnoprotein dimers
(see also Figure 2B). (B) Co-immunoprecipitation of agnoprotein and PCNA. HEK293 cells were transfected with following plasmids: lanes 1 and 2:
pRcCMV-agno plus pFLAG-CMV-2-PCNA, lanes 3 and 4: pRcCMV-agno plus pFLAG-CMV-2, lanes 5 and 6: pRcCMV plus pFLAG-CMV-2. Lanes 1, 3,
and 5: input; lanes 2, 4, and 6: immunoprecipitates (IP). Protein complexes were precipitated with antibodies against PCNA and the presence of
polδ, PCNA and agnoprotein was examined with antibodies against these proteins. (C) FRET measurements of the interaction between
ECFP-PCNA (donor) and EYFP-agnoprotein (acceptor) fusion proteins in A375 cells by acceptor photo bleaching. FRET efficiency (FRET signal %) is
calculated by fluorescence before (prebleach) and after bleaching (postbleach) and shown by the colour code bar. Control experiments with ECFP
plus EYFP-agno and ECFP-PCNA plus EYFP were included.
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respectively), but not in cells not expressing agnoprotein
(lane 6). Since PCNA can interact with pol δ, we tested
whether immunoprecipitation of PCNA resulted in co-
immunoprecipitation of pol δ. Indeed, pol δ was present
using anti-PCNA antibodies in the co-immunoprecipitation
study (bottom panel Figure 1B). These results suggested
that PCNA and agnoprotein interact in vivo and that the
binding of agnoprotein to PCNA did not disrupt the inter-
action between the latter protein and pol δ. We also tried
the reciprocal experiment in which immunoprecipitation
was done with anti-agnoprotein followed by western blot
with anti-PCNA antibodies. However, this did not work in
our hands (see also lane 20 in Figure 1A). Previous studies
and our unpublished results demonstrate that agnoantibo-
dies and PCNA antibodies do not cross-react with GST or
other proteins in different cell lysates. Control experi-
ments with nonspecific antibodies confirm the specificity
of the PCNA:agnoprotein interaction (results not shown
and [47]).
Förster or fluorescent resonance energy transfer (FRET)
relies on distance-dependent energy transfer from a donor
molecule to an acceptor. Because FRET can measure mo-
lecular proximity of less than 10 nm, this method is often
used to examine protein-protein interaction in cells. The
Förster radius R0 is defined as the distance at which 50%
of the energy is transferred and the R0 value for the
donor-acceptor CFP/YFP FRET pair is 4.92 nm [48,49].
To pursue the physical interaction between agnoprotein
and PCNA, we performed FRET by acceptor photobleach-
ing. A375 cells were chosen because they give very high
transfection efficiency and do not easily detach from the
wells of the chamber slides. We observed a FRET effi-
ciency of 25-30% (Figure 1C), strongly indicating a phys-
ical interaction between agnoprotein and PCNA. For
comparison, a positive control existing of the mitogen-
activated protein kinase MK5 and heat shock protein 40
gave a FRET-efficiency of approximately 15% (results not
shown). No interaction was observed when using expres-
sion plasmids for ECFP and EYFP-agno or ECFP-PCNA
and EYFP. Taken together, these findings support that
BKPyV agnoprotein and PCNA can also interact in vivo.
Residues throughout the entire agnoprotein are required
for efficient interaction with PCNA
Several PCNA interaction partners contain a PCNA Inter-
acting Protein box (PIP motif) with consensus sequence
QXXΨXXθ (Ψ = I/M/L, θ = F/Y, X = any amino acid;
[38,50]). A motif with remote similarity is conserved in
the agnoprotein of BKPyV (QRIFIF), JCPyV (QRILIF) and
SV40 (QRLFVF) (Figure 2A). To examine whether this
PIP motif is involved in the interaction with PCNA, we
generated an agnoprotein mutant in which the PIP-like
QRIFIF motif was substituted by ARAFIA (agnomutPIP)and monitored its ability to interact with PCNA. Unfortu-
nately, this mutant was poorly expressed (Additional file 1:
Figure S1). Therefore, we tried another approach, namely
to map the amino acid residues of agnoprotein required to
bind PCNA using pull down experiments with peptide
fragments of agnoprotein. Purified agnoprotein or peptide
fragments spanning amino acids 1–37, 15–45 or 38–66
and PCNA were incubated. We also used a peptide in
which the PIP-like motif QRIFIF was replaced by ARAFIA
(15-45mutPIP). Only full-length agnoprotein bound PCNA
under the experimental conditions (Figure 2B, lane 3),
whereas agnopeptides 1–37, 15–45 and 38–66 failed to do
so (Figure 2B, lanes 5 and 7 and results not shown). This
may indicate that several domains on agnoprotein are cru-
cial for its interaction with PCNA. Similar to peptide 15–
45, GST pull down did not reveal an interaction between
GST-PCNA and peptide 15-45mutPIP. However, as
agnoprotein antibodies did not recognize this peptide
(Figure 2B, lane 8), we cannot completely exclude that
peptide 15-45mutPIP was present in the GST-PCNA pull
down complex.
Anti-agnoprotein antibodies detected a double band
for agnopeptide 15–45 (lane 6), but not for agnopeptide
1–37 (lane 4). JCPyV agnoprotein was shown to form di-
mers that withstand strong denaturating conditions such
as prolonged heating at 95°C, 8 M urea and 20% SDS.
Dimerization of JCPyV agnoprotein requires residues
17–42 [26].
The dimerization domain is highly conserved in BKPyV
agnoprotein (Figure 2A), and in fact BKPyV agnoprotein
was also shown to form dimers [26]. Therefore, the upper
band with agnopeptide 15–45 (lane 6) most likely repre-
sents dimers of 62 (2×31) amino acids compared to 66
amino acids of full-length BKPyV agnoprotein. Agnopep-
tide 1–37 (lane 4) probably lacks the residues crucial for
dimerization and therefore no double band is observed
(Figure 2B, lane 4). The weaker band of approximately 45
kD in lanes 3, 5, 7 and 9 most probably derives from deg-
radation product ([51]; see also lanes 8 and 9 in left panel
Figure 2C and lanes 4 and 8 in right panel Figure 2C).
We performed surface plasmon resonance experiments
using Biacore T100. Again we found that full-length agno-
protein bound PCNA (Additional file 2: Figure S2), but
the peptides either did not bind or displayed unspecific
binding to the chip (results not shown). In conclusion, our
data suggest that the whole agnoprotein rather than a spe-
cific domain of agnoprotein may be necessary for binding
PCNA.
Next, we wanted to map the region of PCNA that is in-
volved in the interaction with agnoprotein. The following
PCNA mutations to Ala were used [52]: PCNASHV43AAA,
PCNAVDK188, PCNAQLGI125, and PCNALAPK251AAAA. Muta-
tion of residues SHV43 within the βC1-βD1 loop results in
































































Figure 2 (See legend on next page.)
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Figure 2 Mapping of the agnoprotein and PCNA regions required for interaction. (A) Amino acid sequences of the agnoproteins of BKPyV,
JCPyV, and SV40 (top part) and schematic representation of BKPyV wild-type agnoprotein (agno WT) and truncated peptides (bottom part). The
conserved “PIP box like sequence” is indicated. The regions encompassing peptides 1–37, 15–45, and 8–66 are indicated by arrows. The number
at the end of the amino acid sequence refers to the number of residues in the protein. The name of the peptides corresponds to the residue
numbers. PIP signifies the PCNA Interaction Protein box and the mutation QRIFIF into ARAFIA is symbolized by an X. (B) GST-pull down of purified
GST-PCNA fusion protein and purified wild-type agnoprotein or agnopeptides. GST-PCNA (lanes 1, 3, 5, 7, 9) was mixed with full-length agnoprotein
(lane 3) or agnoprotein peptide fragments comprising residues 1–37 (lane 5), residues 15–45 (lane 7) or residues 15–45 with mutated PIP motif (lane 9),
respectively. The presence of full-length agnoprotein or peptides and PCNA was monitored by immunoblotting using antibodies against agnoprotein
and PCNA simultaneously. The band representing agnoprotein dimer (lanes 2 and 3) is indicated. The additional weaker bands in lanes 3, 5, 7 and 9
probably represent degradation products. (C) GST-pull down experiments using purified GST-agnoprotein. Left panel: GST-agnoprotein was incubated
with different mutants of PCNA (lanes 3, 5, 7) or GST-PCNA (lane 9) and complexes were pulled down. The presence of agnoprotein and PCNA was
investigated by immunoblotting using antibodies against agnoprotein and PCNA, respectively. M =molecular mass marker in kDa. Right panel:
Coomassie blue staining of purified GST (lanes 2 and 6), GST-agno (lanes 3 and 7) and GST-PCNA (lanes 4 and 8). Lanes 1 and 5: Precision Plus Protein
Dual Color Standards (BioRad) marker.
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ase δ activity [38]. VDK188 in the loop between βD2
and βE2 is part of the most eye-catching feature in the
PCNA structure and the residues are conserved in plant
and vertebrate PCNA. Likewise, the LAPK251 motif is
conserved in all known PCNA sequences [52,53]. The
PCNALAPK25AAAA mutant could not be used since this
one is unstable [our observation and 52]. In vitro pull
down assays demonstrated that none of these mutations
affected the binding of agnoprotein (Figure 2C). These
results demonstrate that amino acid residues of PCNA
which are involved in the interaction with other pro-
teins are not required for agnoprotein binding.
Agnoprotein affects PCNA-dependent DNA replication
in vitro
Since PCNA is involved in DNA replication, a putative
role for the agnoprotein may lay in stimulating or turn-
ing off viral DNA replication late in the viral life cycle
by targeting PCNA. Because agnoprotein expression oc-
curs at a later stage of the infection cycle, it is more
probable to assume that agnoprotein suppresses viral
DNA replication by perturbing PCNA’s function and
allowing assembly of virions. We first examined whether
agnoprotein could interfere with PCNA-mediated in vitro
DNA replication. Because PCNA acts as a sliding platform
for pol δ in DNA replication, we measured the effect of
agnoprotein on PCNA:pol δ-mediated DNA synthesis.
Decreased DNA synthesis activity was registered in
the presence of increasing agnoprotein concentrations.
PCNA:pol δ-mediated DNA replication was reduced
by approximately 50% when 100 ng agnoprotein were
added (Figure 3A left panel). In contrary, PCNA alone
(results not shown) or together with increasing concen-
trations of agnoprotein were unable to affect pol λ-
mediated DNA synthesis (Figure 3A, right panel). To
assure that inhibition of DNA synthesis by agnoprotein
occurred through interaction with PCNA and is not adirect effect on pol δ, we pre-incubated different combi-
nations of two proteins for 5 min (either PCNA plus pol
δ, pol δ plus agnoprotein, or PCNA plus agnoprotein)
thus allowing them to interact, followed by the addition
of the third protein and the primer/template DNA. The
products of DNA synthesis were separated under de-
naturing conditions on an acrylamide gel. No inhibitory
effect was observed in case of pre-incubation of PCNA
and pol δ and pursued with agnoprotein (Figure 3B, lanes
2–5) or pre-incubation of agnoprotein and pol δ,
followed by the addition of PCNA (Figure 3B, lanes 6–9).
However, allowing PCNA and agnoprotein to interact
prior to the addition of pol δ, suppressed DNA synthesis
(Figure 3B, lanes 10–14). PCNA alone did not support
DNA replication (Figure 3B, lane 15), while pol δ alone is
able to synthesize DNA, although less processive when
compared to the reaction in which PCNA is present as
well (Figure 3B, compare lane 2 and lane 17). The re-
duced signal in lanes 10 and 11 can probably ascribed to
some variation in the template input.
To assure that agnoprotein does not act as an unspe-
cific inhibitor of the pol activity, a dose–response experi-
ment with increasing concentrations of agnoprotein in
the presence of constant amounts of pol λ was set up.
Pol λ alone, but neither PCNA nor agnoprotein, was
able to trigger DNA elongation on an incomplete double
stranded oligonucleotide (compare lanes 7, 8, and 14 in
Figure 3C). As pol λ is a PCNA-independent pol, no
changes in DNA synthesis were visible when increasing
amounts of PCNA were added to pol λ (Figure 3C, lanes
2–6). Likewise, agnoprotein had no effect on in vitro pol
λ-mediated DNA elongation (Figure 3C, lanes 9–13).
Accordingly, agnoprotein did not interfere with pol β-
mediated DNA synthesis (results not shown). In con-
clusion, our results suggested that the agnoprotein
specifically inhibits pol δ-mediated DNA synthesis in vitro
through targeting PCNA, but does not affect PCNA-
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Figure 3 (See legend on next page.)
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Figure 3 Agnoprotein inhibits in vitro DNA replication mediated by PCNA:DNApolymerase δ. (A) Left panel: In vitro DNA synthesis by
PCNA plus pol δ was monitored in the presence of increasing amounts of agnoprotein. DNA synthesis in the presence of pol δ alone was
arbitrary set as 1 and the increase by adding PCNA is shown as fold PCNA stimulation. Right panel: Pol λ-mediated DNA synthesis was monitored
in the presence of variable nM ratios of agnoprotein:PCNA. Incorporation of radioactivity was measured by scintillation counting. (B) DNA synthesis
was assayed by monitoring elongation of a partially double-stranded 39:72 oligonucleotide dimer (=template DNA). Lanes 1 and 16: 32P-labelled
template DNA; lanes 2–5: PCNA and Pol δ were allowed to interact before template DNA and increasing amounts of agnoprotein were added; lanes
6–9: agnoprotein and pol δ were pre-incubated before supplementing PCNA and template DNA; lanes 10–14: agnoprotein and PCNA were mixed prior
to the addition of pol δ and template DNA; lane 15: PCNA and template DNA; lane 17: template DNA and pol δ. The upper symbol (=) represents the
elongated DNA template, while the lower symbol (− ) is the template. (C) Pol λ-mediated DNA synthesis in the presence of PCNA or agnoprotein. The
upper band is ssDNA, the middle band is dsDNA, while the lower band represents incomplete dsDNA. Lanes 2–6: increasing amounts of PCNA were
added; lanes 9–14: increasing amounts of agnoprotein were added; lane 1: template DNA; lane 8: DNA was incubated with only pol λ. DNA synthesis
was visualized by autoradiography as described in 3B. The upper symbol (=) represents the elongated DNA template, while the lower symbol (− ) is
the template.
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Next, we wanted to access an effect of agnoprotein on
PCNA-mediated DNA replication in vivo. A375 cells
were transfected with expression plasmids for agnopro-
tein or/and PCNA. Control cells were transfected with
empty expression plasmid. A375 were chosen because
they have very high transfection efficiency and in contrast
to HEK293 cells they do not easily detach. Forty-eight
hours after transfection, cell proliferation was measured
by the MTT assay (Figure 4). Ectopic expression of agno-
protein inhibited cell proliferation by 21% (p < 0.001).
Overexpression of PCNA had no significant effect on cell
proliferation (94% proliferation compared to control; p =
0.04). Co-expression of agnoprotein and PCNA partially
restored agnoprotein-mediated inhibition of cell prolifera-
tion to 86% compared to control cells (p = 0.001). These
results suggest that agnoprotein-induced repression of cell
proliferation involves PCNA.
Discussion
The role of PyV agnoprotein remains puzzling because
the gene encoding this protein is not present in the
genomes of all members of the Polyomaviridae, while all
other viral genes are well-conserved. To unveil the bio-
logical importance of BKPyV agnoprotein, we set out to
identify cellular interaction partners by a yeast two-hybrid
screen. PCNA was found to bind directly to agnoprotein
by GST-pull down assays. Co-immunoprecipitation and
FRET studies confirm in vivo interaction between PCNA
and agnoprotein. Agnoprotein:PCNA complexes could be
co-immunoprecipitated using anti-PCNA antibodies, but
the reciprocal precipitation did not work in our hands
even though we tried different experimental conditions.
We reason that since agnoprotein is small (66 amino
acids), its interaction with PCNA may prevent anti-
agnoprotein antibodies to bind due to steric hindrance.
We therefore tried immunoprecipitation of GAL4-
tagged agnoprotein (147 amino acid tag) with anti-
GAL4 antibodies, but were also unsuccessful. The
reason is unknown, but the GAL4 moiety may changethe conformation of agnoprotein, making it impossible
to interact with PCNA. Studies with shorter tags (e.g.
HA or myc) may circumvent this problem.
Regions required for agnoprotein:PCNA interaction
Many of the PCNA interacting proteins contain a PIP box
with consensus sequence QxxI/M/LxxF/Y [38,50]. BKPyV
agnoprotein contains a QRIFI motif with remote hom-
ology to the PIP box. Agnopeptide fragments spanning
residues 1–37 and 15–45 were unable to bind PCNA,
despite the presence of the putative PIP-like motif. Co-
immunoprecipitation studies using extracts of cells trans-
fected with a plasmid encoding full-length agnoprotein
with PIP mutation were unsuccessful because this mutant
was not expressed at detectable levels, probably due to in-
stability of the protein. None of the agnopeptide fragments
tested (peptides encompassing residues 1–37, 15–45 or
38–66) were able to interact with PCNA in our assay.
Several PCNA-interacting proteins have been isolated
that lack an obvious PIP box. In fact, none of the 14
cytoplasmic proteins that bind PCNA contain the ca-
nonical PIP box [54]. Gilljam and colleagues identified
another shared motif in PCNA-interacting proteins
without a clear PIP box; the AlkB homologue 2 PCNA-
interacting motif (APIM). The APIM motif consists of
K/RFIVK/R flanked on both sides by a K and/or R. This
motif is common in proteins involved in DNA mainten-
ance and cell cycle regulation after DNA damage [55].
BKPyV agnoprotein does not contain an APIM-like se-
quence. None of the mutations in the SHV, VDK, QLGL
motifs of PCNA abrogated the interaction with agnopro-
tein. Although some of these motifs are implicated in
the interaction with cellular proteins such as pols δ and
ε, replication factor C, p21 and flap endonuclease 1
[52,53], they are dispensable for binding agnoprotein.
PCNA, agnoprotein, and DNA polymerase δ: binary or
ternary complexes?
Pull down with anti-PCNA antibodies of lysates derived






















Figure 4 Agnoprotein inhibits cell proliferation. A375 cells were
transfected with empty expression plasmid pRcCMV (CTRL), expression
plasmid for agnoprotein (Agno), expression plasmid for PCNA, or
expression plasmids for agnoprotein and PCNA, respectively. (A) Cell
proliferation was measured by the MTT method 48 hours after
transfection. The value obtained for pRcCMV-transfected cells was
arbitrary set as 100% and the values for the other cells were related to
this. The values are the average of six independent parallels measured
in triplicate. The standard deviation is shown and a student’s t-test was
performed. Similar results were obtained in a separate experiment.
(B) Ectopically expressed agnoprotein and FLAG-tagged PCNA were
detected by western blot on lysates of transfected cells using
anti-agnoprotein and anti-FLAG-specific antibodies. Lane 1: lysates of
cells transfected with empty expression plasmid pRcCMV; lane 2: lysates
of cells transfected with pRcCMV-agnoprotein expression plasmid; lane
3: lysates of cells transfected with an expression plasmid encoding
FLAG-tagged PCNA; lane 4 lysates of cells co-transfected with
expression plasmids for agnoprotein and FLAG-tagged PCNA. To assure
equal loading, expression levels of ERK2 in each lysate were determined
(bottom panel).
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comparable pol δ levels in the immunoprecipitates. This
may indicate that agnoprotein and pol δ bind PCNA in
a non-exclusive manner to form a ternary complex. In-
deed, if agnoprotein would compete with pol δ to bind
PCNA, less pol δ would be expected in immunoprecipi-
tates of cells expressing agnoprotein compared to non-agnoprotein expressing cells. Agnoprotein and pol δ may
bind to different regions of PCNA or pol δ is the bridging
molecule that connects agnoprotein and PCNA. In vitro
GST-pull down studies, however, demonstrated a direct
interaction between PCNA and agnoprotein. We have not
investigated whether agnoprotein bound to PCNA also in-
teracts with pol δ.
Mode of action for agnoprotein-mediated inhibition of
PCNA: DNA polymerase δ DNA replication
The precise mechanism by which agnoprotein sup-
presses PCNA:pol δ-mediated DNA synthesis remains
unsolved. One obvious possibility is that agnoprotein
disrupts the interaction between PCNA and pol δ. How-
ever, studies with lysates of cells overexpressing agnoprotein
and PCNA, showed that protein complexes immunopreci-
pitated with PCNA antibodies contained all three proteins:
PCNA, pol δ, and agnoprotein (Figure 1B). This indicates
that agnoprotein does not disrupt the interaction between
PCNA and pol δ. Another mechanism is that binding of
agnoprotein to PCNA neutralizes the enzymatic activity of
PCNA or prevents the PCNA:pol δ complex to bind to
template DNA. A third mechanism to explain the inhibi-
tory effect of agnoproteins is by targeting pol δ. Our
in vitro DNA elongation studies do not indicate that agno-
protein alone hampers pol δ-driven DNA synthesis, but it
is possible that agnoprotein after it is recruited by PCNA
can inhibit pol δ activity, which is in accordance with our
results. Finally, agnoprotein may negatively interfere with
PCNA:pol δ-mediated replication by down-regulating the
expression of PCNA. This seems unlikely because all our
co-immunoprecipitation studies were done in cells overex-
pressing agnoprotein and we could vividly detect PCNA.
Moreover, PCNA protein levels in cells overexpressing
agnoprotein were similar to cells not expressing agno-
protein (compare lanes 1,3 and 5 in Figure 1B, and our
unpublished results).
Functional implication of the agnoprotein-PCNA interaction
Replication of the PyV genome depends mostly on host
cell proteins. The only viral protein absolutely necessary
for viral replication is large T-antigen [1]. Recent studies
have shown that agnoprotein-deficient polyomaviruses
JC and SV40 display lower viral DNA replication, but
also reduced large T-antigen expression levels compared
to wild-type viruses [33,56]. A difference between cellu-
lar and viral DNA replication seems to be the involve-
ment of different polymerases. The host cell requires pol
ε for the replication of the leading strand, while pol δ
synthesizes the lagging strand [39,41]. However, pol δ is
also capable of performing leading strand synthesis
[39,41]. This is illustrated during SV40 infection, when
DNA replication only relies on pol δ [57,58]. Pol δ is a
PCNA-dependent pol [38]. As the viral replication cycle
Gerits et al. Virology Journal  (2015) 12:7 Page 10 of 14proceeds, a switch from producing viral genomes to syn-
thesizing viral capsid proteins and assembling virions is
required. Agnoprotein could play a regulatory role by
turning of viral DNA synthesis through inhibiting
PCNA:pol δ-mediated DNA replication. Because cellular
DNA replication also depends on pol δ, agnoprotein will
also suppress this process. Indeed, we found that expres-
sion of agnoprotein inhibited cell proliferation and this
effect was counteracted by co-expressing PCNA.
Viruses can prevent apoptosis, which allow them to
replicate. They can also induce apoptosis to enable viral
shedding from the infected cells [59]. By leaving within
apoptotic bodies, viruses may spread to surrounding
cells and macrophages without provoking a strong im-
mune/inflammatory response [60-62]. PCNA has been
shown to prevent apoptosis in neutrophils [63]. As agno-
protein is expressed late during the viral infection cycle,
it is plausible that agnoprotein triggers apoptosis of the
infected cell in order to disseminate newly produced vi-
rions. Indeed JCPyV agnoprotein has been shown to pro-
mote apoptosis, but the implication of PCNA was not
investigated [37,64]. Neutrophils undergoing apoptosis
witness a degradation of PCNA by the proteasome, while
overexpression of PCNA rescues apoptosis of neutro-
phils. This anti-apoptotic property of PCNA depends on
cytoplasmic location of PCNA [63]. Because we ob-
served that BKPyV agnoprotein did not reduce the ex-
pression levels of PCNA (see above), it might exert its
apoptotic effect by sequestering cytoplasmic PCNA.
PCNA:DNA pol δ is also involved in the base excision
repair pathway [46]. The interaction of agnoprotein with
PCNA may therefore perturb PCNA:DNA pol δ −
dependent DNA repair, resulting in an accumulation of
mutations. Agnoprotein may in this way contribute to
transformation of BKPyV-infected cells.
Conclusions
Our study identifies PCNA as a novel BKPyV agnopro-
tein interaction partner and demonstrates that agnopro-
tein impedes with the auxiliary function of PCNA in pol
δ-mediated DNA synthesis. Given the fact that agnopro-
tein is expressed late during the viral cycle, it would
seem plausible that such an interaction serves to termin-
ate viral DNA replication so that virus particles can be
assembled. At the same time, agnoprotein may promote
apoptosis in a PCNA-dependent manner and enhance
the release of virions. Both these putative roles of agno-
protein need further investigations. Agnoprotein does
not only facilitate viral dissemination, it also possesses
oncogenic potentials and has been detected in human
tumours. Its role in carcinogenesis, however, remains to
be proven [65,66]. One of the oncogenic properties
could rely on agnoprotein’s ability to increase the error
rate of DNA replication and repair by targeting PCNA.Agnoprotein may therefore be an attractive target in ma-
lignant and non-malignant pathologies.
Methods
Materials
PCNA (C-10) and pol δ (p125) antibodies were from
Santa Cruz Biotechnology (Santa Cruz, CA, USA), while
ERK2 was purchased from Cell Signalling Technologies,
Inc (Danvers, MA, USA). Antibody against BKPyV agno-
protein has been described previously [67]. Alkaline
phosphatase-conjugated and horse radish peroxidase-
conjugated secondary antibodies were purchased from
Dako (Denmark). Thrombin protease was from Amersham
Biosciences (GE Healthcare Bio-Sciences AB, Uppsala,




and residues 15-45mutPIP (GKTWTGTKKRAARAFIA
ILELLLEFCRGED) were synthesized by Gene Cust
(Luxembourg) and were dissolved in H20. Primers for
site-directed mutagenesis (the complementary primer is
not shown) PIP box (5’-A AAA AGA GCT GCG AGG
GCT TTT ATT GCT ATT TTA GAG C-3’), K164R (5’
GTA ATT TCC TGT GCA AGA GAC GGA GTG 3’),
PCNA_SHV43 (5’- CAT GGA CTC GGC CGC CGC
CTC TTT GGT-3’), PCNA_VDK188 (5’- ACA AGT AAT
GCC GCT GCA GAG GAG GAA-3’), and PCNA_
QLGI125 (5’- TAG ATG TTG AAG CCG CTG CAG
CTC CAG AAC A-3’) were from Sigma Aldrich (St. Louis,
MO, USA). The sequence of the 72-mer is: ATGTT
GGTTCTCGTATGCTGCCGGTCACGGCTTAAGTGT
GGCGGCCGCGGGTTGGAGGGCTTATAGATTATG,
and the sequence of the 39-mer is complementary to the
underlined region in the 72-mer [68].
Plasmids
The empty expression vector pRcCMV was purchased
from Invitrogen (Invitrogen Life Technologies, Grand
Island, NY, USA). The plasmid pRcCMV-agno which en-
codes BKPyV agnoprotein has been previously described
[7]. Plasmid pFLAG-CMV-2 was obtained from Sigma
Aldrich, while pFLAG-CMV-2 PCNA expression vector
was a kind gift of Hong-Gang Wang [69]. pGST-agno
has been described previously [34].
Cells
HEK 293 cells (ECACC cat. No. 85120602) were pur-
chased from the European Collection of Cell Culture
(ECACC) and were maintained in DMEM with 10%
foetal bovine serum (FBS; Sigma Aldrich) in the presence
of 100 μg/ml streptomycin and 100 units/ml penicillin.
The human melanoma cell line A375 was obtained from
American Type Culture Collection (ATCC cat. no. CRL-
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streptomycin (100 μg/ml), and penicillin (100 units/ml).
Western blot
Samples were analysed by 10-20% SDS-PAGE Bis-Tris
glycine ClearPage gels (Invitrogen Life Technologies) ac-
cording to the manufacturer’s protocol and blotted onto
a 0.45 μm PVDF membrane (Millipore, Billerica, MA,
USA). Immunoblotting was performed by first blocking
the membrane with PBS-T (PBS with 0.1% Tween-20;
Sigma Aldrich) containing 10% (w/v) dried skimmed
milk for 1 hour and probed with the appropriate primary
antibody overnight at 4°C. After 3 washes, the mem-
brane was incubated with the appropriate secondary
antibody for 1 hour at room temperature. After 4
washes, antigen-antibody complexes were visualized
using CDP Star (Tropix, Bedford, MA, USA) substrate
and Lumi-Imager F1 from Roche (Basel, Switzerland).
Magic-Mark™ Western standard from Invitrogen Life
Technologies was used to estimate the molecular mass
of the detected proteins.
Immunoprecipitation
HEK293 cell extracts were harvested and lysed in buffer
containing PBT (PBS + 0.1% Triton X100) and Complete
Protease Inhibitor Cocktail (Roche Diagnostics Norway).
Lysates were cleared by centrifugation at 4°C for 10 mi-
nutes at 15,000 g and incubated with the appropriate
antibody for 1 hour at 4°C, before addition of 60 μl
slurry (i.e. 30 μl protein G-agarose (GE Healthcare)
equilibrated with 30 μl lysis buffer) and incubated for an
additional hour. The immunoprecipitates were then
washed three times in lysis buffer and twice in 20 mM
Hepes pH 8.0. Twenty μl 2xLDS sample buffer was
added to the beads before denaturation at 70°C for
10 minutes. The immunoprecipitates were analysed on
western blots.
Protein purification
GST-agnoprotein and mutant proteins were purified from
Escherichia coli BL21 bacteria according to the protocol of
the manufacturer. Briefly, GST-agarose beads were washed
three times with PBT (PBS + 0.1% TritonX100). After cen-
trifugation, bacteria were lysed in PBT containing protease
inhibitor cocktail and the lysate was cleared by centrifuga-
tion. The supernatant was transferred to 15 ml tubes and
50% beads were added for 1 h incubation at 4°C. Then the
beads were collected and washed twice with PBT and
twice with PBS. GST cleavage was performed with throm-
bin for 2 h at RT. Alternatively, glutathione was added and
two elution steps were used to assure that all GST-
coupled protein was recovered. GST and GST fusion pro-
teins were dissolved in PBS. Protein yield was checked on
SDS-PAGE gels with Coomassie staining. Pols β, δ, λ andPCNA recombinant proteins were purified as previously
described [68,70].
Yeast two hybrid screen
Yeast-two hybrid screen was performed by PanBionet
(Pohang, South Korea) with BKPyV agnoprotein as bait
against human kidney and thymus libraries. Transfor-
mants were spread on selection media (SD-LWU) where
yeasts with bait and prey interacting together could the-
oretically grow. The yeast colonies on uracil deficient
media were analysed for other reporter expression (lacZ
and ADE2) under the control of a different GAL4-
dependent promoter. Through the screening of the two
libraries, 53 Ura + colonies were obtained, 28 from the
kidney library and 25 from the thymus library. Only 12
of colonies showed expression of other reporter genes
ADE2 and lacZ (3 from the kidney and 9 from the thy-
mus library). Since only a small number of candidates
were obtained, prey plasmids were isolated from all Ura +
candidates from both libraries. The prey DNAs were amp-
lified by PCR from the purified DNAs. In order to recon-
firm the interaction, the preys were reintroduced into
yeast with agnoprotein bait or with empty bait plasmid
containing only GAL4-DNA binding domain lacking
agnoprotein. Most of the prey plasmids tested showed
self-activator activities. Some candidates which did not re-
produce the reporter expression were retested with preys
isolated by conventional E. coli transformation with yeast
purified DNAs.This approach resulted in 6 putative inter-
action partners for BKPyV agnoprotein and one of them
was PCNA.
DNA replication assays
PolyA-oligodT served as a template for DNA replication
assays presented in Figure 3A, while in Figures 3B-C
labelled 39/72-mer primer template was used. Annealing
of the polydA-oligodT (0.5 mg/ml) was done using a
10:1 polydA/oligodT ratio with Tris–HCl pH 8 for
5 min at 65°C in a heat block followed by addition of
20 mM KCl and left to cool down slowly. A 39-mer pri-
mer was labelled by incubating T4 Polynucleotide kinase
buffer, Polynucleotide kinase enzyme (New England Bio-
loabs, Ipswich, MA, USA), 32P-γ ATP (3000 Ci/mmol;
PerkinElmer Waltham, MA, USA) and 39-mers for 20 min
at room temperature and 20 min at 37°C, heat-inactivated
at 80°C for 10 min, centrifuged on MicroSpin columns
(GE Healthcare Life Sciences) to remove the excess of un-
incorporated radioactive label. The radioactively labelled
39-mer was then annealed to a 72-mer template in anneal-
ing buffer, heated to 95°C for 10 min, and subsequently
left to cool down overnight. The pol δ assays were per-
formed in presence of 50 mM BisTris pH6.5, 1 mM DTT,
0.25 mg/ml BSA, 5 mM MgCl2 and 2 nM labelled 39/72-
mer primer template (Figure 3) or 10 μM 3[H]dTTP
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left panel) PCNA, pol δ and agnoprotein were added in
quantities indicated in figures and figure legends. The
reactions were incubated at 37°C for 30 minutes and
stopped by addition of 10%TCA (Figure 3A, left panel) or
stop buffer (2x stop buffer is 96% formamide (v/v), 20 mM
EDTA, bromophenol blue and xylene cyanol) (Figure 3B).
In the former case results were analysed by scintillation
counting (Vtotal=50 μl), in the latter case by sequencing
gels (Vtotal=25 μl). For the pol λ or β assays, λ buffer (10x
λ buffer is 500 mM Tris–HCl pH7.5; 10 mM DTT,
2.5 mg/ml BSA), 0.8 mM MnCl2, , and 2 nM labelled 39/
72-mer primer template (Figure 3C) or 20 μM polydA/
oligo dT with 50 μM [3H]-dTTP (400 cpm/pmol)
(Figure 3A, right panel) were prepared as a premix. Puri-
fied pols λ or β and agnoprotein were added to 25 μl reac-
tion mixture containing polydA/oligo dT and [3H]-dTTP
and incubated at 37°C for 30 min, followed by addition of
10% TCA and analysis by scintillation counting. Polymer-
ase λ or β and agnoprotein were incubated with the premix
containing labelled 39/72-mer primer template (Figure 3C)
in a final volume of 10 μl. Reactions were incubated at
37°C for 15 min and stopped by addition of the stop buf-
fer. Reaction products were analysed on a sequencing gel.
MTT assay
A375 cells were seeded out at 5×104 cells per well in a
24-well plate. The next day, cells were transfected by Li-
pofectamine 2000 (Invitrogen) with empty expression
pRcCMV, or a plasmid encoding BKPyV agnoprotein,
PCNA or both. The amount of DNA in each sample was
kept constant by adding calf thymus DNA. Forty-eight
hours after transfection, MTT (3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide; Sigma- Aldrich) was
added to a final concentration of 0.5 mg/ml and the cells
were incubated for 2 hours at 37°C. Then stop solution
(isopropanol containing 0.04 N HCl) was added and the
cells were incubated for 1 hour at room temperature.
Thereafter, 3×100 μl of each well was transferred to new
wells of a 96-well plate. Absorbance at 570 nm was mea-
sured in a Molecular Devices VERSAmax microplate reader
(Molecular Devices LLC, Sunnyvale, CA, USA).
Fluorescence resonance energy transfer (FRET) studies
The oligonucleotides 5’-GCAGTCGACATGTTCGAGGC
GCGCCTGGTC-3’ and 5’- TATGCGGCCGCCTAAGA
TCCTTCTTCA-3’ were used to amplify the PCNA cDNA
sequence from pFlag-CMV-PCNA. Then, the PCR frag-
ment was cut with SalI/NotI and ligated into the corre-
sponding sites of pENTR1A (Invitrogen). The plasmid
pGST-agno was digested with EcoRI/NotI, and the frag-
ment ligated into the corresponding sites of pENTR3C
(Invitrogen). The resulting pENTR-PCNA and pENTR-
agno were further recombined with Gateway destinationvectors pDest-ECFP and pDest-EYFP (a gift from Dr. T.
Johansen), respectively, generating EYFP-agno and ECFP-
PCNA. For FRET analysis, A375 cells were co-transfected
with ECFP-PCNA and with EYFP-agno using TransIT-
LT1 transfection reagent (Mirus Bio LLC, Madison, WI,
USA). Then, 24 hrs after transfection, the cells were fixed
with 4% formaldehyde. FRET analysis was carried out with
Leica TCS SP5 confocal microscope with a × 63, 1.2 W ob-
jective. CFP and YFP were excited with separate laser
channels of 458 nm and 514 nm, respectively. Emission
fluorescence intensity data were obtained at 465–500 nm
(CFP) and 525–600 nm (YFP). CFP and YFP emission sig-
nals were captured before and after 25% photo bleaching
YFP. FRET is indicated as the relative increase in CFP
emission following YFP photo bleaching. The imaging sys-
tem was controlled by the Leica Application Suite Ad-
vanced Fluorescence (LAS AF) software (http://www.
leicamicrosystems.com).
BIAcore
The association between agnoprotein and PCNA were
measured with a BIAcore T100 instrument (BIAcore,
Uppsala, Sweden). Standard sensor chips, amine coup-
ling kit containing N-hydroxysuccinimide, 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide hydrochloride, running
buffer 10xHBS-EP+, regeneration solution, immobilization
buffers and 1 M ethanolamine hydrochloride, all pur-
chased from Biacore (Biacore, Sweden), were used for the
measurements. Analyses were performed with the Biacore
T100 control software and Biacore T100 evaluation soft-
ware 1.1 using the Langmuirmodel for 1:1 ligand inter-
action to determine the association (ka) and dissociation
(kd) constants and calculation of the KD value.
Additional files
Additional file 1: Figure S1. The agnoprotein mutant in the putative
PIP motif is poorly expressed. HEK293 cells were transfected with expression
plasmids for agnoprotein (agno; lane 2), agnoprotein in which the PIP-like
motif was mutated (lane 3; agnomutPIP), or empty expression plasmid (empty
vector, lane 4). Cell lysates were prepared and the expression of agnoprotein
(top panel) or PCNA (bottom panel) was monitored by western blotting
using anti-agnoprotein and anti-PCNA antibodies, respectively. Lane 1:
protein size marker (in kD).
Additional file 2: Figure S2. Biacore measurements to study in vitro
interaction between recombinant PCNA and agnoprotein. PCNA (20–
30 μg/ml) was immobilized on a CM5 chip. Binding properties of PCNA
antibody (positive control), BSA (negative control) and WT agnoprotein
(10 μg per injection) to PCNA were assessed. The sensorgram on the left
depicts the results obtained with PCNA antibody (green) and BSA (blue),
while the sensorgram on the right depicts the binding profile of WT
agnoprotein (red). Responses are given in resonance units (RU) in
function of time, where 1000RU corresponds to a change in 0.1 degree
in resonance angle.
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